Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Unknown 26Completed 14Recruiting 13Not yet recruiting 12Active not recruiting 5Terminated 3No longer available 1

Sponsor Class

OTHER 5

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Gastrointestinal 3NET 1Gynecologic 1Endocrine 1

Conditions

Pancreatic Neoplasms 2Ovarian Neoplasms 1Neuroendocrine Tumors 1Cholangiocarcinoma 1

Interventions

pembrolizumab 437Carboplatin 322Nivolumab 292Cyclophosphamide 281Specimen Handling 271Magnetic Resonance Spectroscopy 257Cisplatin 253Paclitaxel 248Radiotherapy 229Gemcitabine 183Biopsy 182Dexamethasone 181durvalumab 168atezolizumab 151Rituximab 138Doxorubicin 135Lenalidomide 134Bevacizumab 133Docetaxel 131Ipilimumab 129Capecitabine 120Radiation 118Oxaliplatin 114Radiosurgery 113Pemetrexed 112Etoposide 111Fluorouracil 110venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × surufatinib × Clear all
NCT07534371 2026-04-16

Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study

West China Hospital

Active not recruiting
500 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05908747 2026-02-10

Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Active not recruiting
29 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05481476 2025-09-04

Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

Sun Yat-sen University

Phase 2 Active not recruiting
32 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05652283 2024-11-27

Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Anhui Provincial Cancer Hospital

Phase 2 Active not recruiting
37 enrolled
Gynecologic

Ovarian Neoplasms

NCT06239532 2024-11-21

HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

Qilu Hospital of Shandong University

Phase 2 Active not recruiting
28 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡